This page lists past opportunities from CIP.
Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.
Contact: Keyvan Farahani, Ph.D. (email@example.com) at 240-276-5921
The NCI encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This initiative will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first in human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this initiative.
See full description in NIH Guide: PA-09-253
Anne Menkens, Ph.D. (firstname.lastname@example.org) at 301-496-9531
The Cancer Imaging Program, and the Division of Cancer Diagnosis and Treatment, at the National Cancer Institute (NCI), invite new or renewal (competing) applications for P50 Research Center Grants for In vivo Cellular and Molecular Imaging Centers (ICMICs). The program will fund the 5-year P50 ICMIC grants to support interdisciplinary scientific teams conducting cutting-edge cancer molecular imaging research. ICMIC funding is designed to: (1) support innovative cancer molecular imaging research projects; (2) support unique core facilities; (3) enable the awardees to initiate pilot research in new promising directions; and (4) provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging.
See full description in NIH Guide:PAR-09-157
Robert J. Nordstrom, Ph.D. (email@example.com) at 301-594-9121
The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees will form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.
See full description in NIH Guide: PAR-08-225